ArticleActa pharmaceutica Sinica. B2025
Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy.
Yu Guo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it